Lantern Pharma Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational therapy LP-284 for the treatment of soft tissue sarcomas, marking the third such designation for this compound and the sixth across the company’s AI-driven oncology pipeline. This designation expands LP-284’s potential use into solid tumors, addressing a rare cancer with limited treatment options and supporting Lantern’s precision oncology development efforts.
